Key Points {#FPar1}
==========

In a large cohort (*N* = 1708) of patients with treatment-resistant depression who had no clinically important cardiovascular disease or had hypertension controlled by antihypertensive medications, adverse events of esketamine nasal spray were transient and manageable in a clinical setting under the observation of a healthcare professional.In general, blood pressure elevations following dosing of esketamine nasal spray were short-lived, were not associated with symptoms, rarely required treatment with antihypertensive medication, and did not result in serious cardiovascular safety sequalae.Esketamine nasal spray has no clinically relevant treatment-emergent effect on the duration of mean electrocardiogram intervals.

Introduction {#Sec1}
============

Ketamine, an antagonist of the glutamatergic *N*-methyl-*D*-aspartate (NMDA) receptor (an ionotropic glutamate receptor), was shown to exhibit rapid onset and robust, short-term antidepressant effect in patients with treatment-resistant depression (TRD) \[[@CR1]--[@CR3]\]. Esketamine, the *S*-enantiomer of ketamine racemate, was recently approved by the United States (US) Food and Drug Administration (FDA) and by the European Medicines Agency (EMA) as an intranasal formulation for adults with TRD based on efficacy and safety findings from short-term phase II/III studies \[[@CR4]--[@CR9]\] and longer-term phase III studies \[[@CR7], [@CR8]\].

Transient cardiovascular stimulatory effects have been reported with ketamine, beginning shortly after dosing for general anesthesia \[at doses of 0.5--2 mg/kg intravenously (IV)\], including increase in arterial blood pressure (BP), heart rate, and cardiac output \[[@CR10]\]. Although ketamine has direct cardio-depressant and negative inotropic effects, the indirect sympathomimetic effect dominates in physiological conditions \[[@CR11]\]. This is triggered by a systemic release of catecholamines, inhibiting the vagal nerve and inhibiting norepinephrine and epinephrine reuptake at peripheral nerves and within the myocardium \[[@CR11]\]. While the exact mechanism is unknown, ketamine is considered to have sympathomimetic effects by influencing calcium influx \[[@CR12]\].

In a recently published study, IV infusion of ketamine (0.5 mg/kg over 40 min) in patients with major depressive disorder was associated with mean systolic BP (SBP) and diastolic BP (DBP) increase by \~ 3 mmHg at peak, 30 min into the infusions, and returned toward baseline levels shortly thereafter \[[@CR13]\]. Wan et al. \[[@CR14]\] reported higher transient BP increases (peak increase of 19.6/13.4 mmHg based on 205 ketamine infusions) \[[@CR14]\]. These cardiovascular effects may complicate treatment of patients with TRD who, in real-world settings, often have hypertension (67%) and cardiovascular disease (56%) \[[@CR15]\].

It is important to characterize the cardiovascular effects of esketamine, given that patients with major depression/TRD are at increased risk of cardiac morbidity/mortality \[[@CR16], [@CR17]\]. We report herein the cardiovascular effects of esketamine nasal spray, adjunctive to an oral antidepressant, in a large cohort of patients with TRD who were treated in the esketamine clinical development program.

Materials and Methods {#Sec2}
=====================

Study Design {#Sec3}
------------

The cardiovascular safety analysis population came from five double-blind, placebo-controlled, phase II/III studies and one open-label phase III study of esketamine nasal spray in adults with TRD (Table [1](#Tab1){ref-type="table"} \[[@CR4]--[@CR9]\]).Table 1Studies of esketamine nasal spray included in analysesClinical study, yearStudy designEsketamine dosingNumber of patientsEsketamine nasal spray + oral antidepressantOral antidepressant + placeboDaly et al., 2018 \[[@CR4]\]Phase II, dose-ranging, DB, doubly R, delayed-start, PC study of adults (20--64 years) with TRDDB: 28, 56, or 84 mg twice weekly for two 1-week DB periodsOL: 28, 56, or 84 mg twice weekly for the first 2 weeks, QW for the next 3 weeks, then once QOW106^a^54^b^Fedgchin et al., 2019 (TRANSFORM-1) \[[@CR5]\]Phase III, R, DB, AC study of adults (18--64 years) with TRDFixed dosing: 56 or 84 mg twice weekly for 4 weeks231113Popova et al., 2019 (TRANSFORM-2) \[[@CR6]\]Phase III, R, DB, AC study of adults (18--64 years) with TRDFlexible dosing: 56 or 84 mg twice weekly based on efficacy and tolerability for 4 weeks115109Daly et al., 2019 (SUSTAIN-1) \[[@CR7]\]Phase III, R, DB withdrawal study of adults (18--64 years) with TRDOL induction phase: flexible dosing: 56 or 84 mg twice weekly for 4 weeks; responders proceeded to optimization (12 weeks) and maintenance (variable duration) treatment during which frequency was QW or QOW based on severity of depressive symptoms619^c^145^d^Wajs et al., 2020 (SUSTAIN-2) \[[@CR8]\]Phase III, OL safety study of adults and elderly patients (≥ 18 years) with TRD28 mg (elderly) and 56 mg (18--64 years) to start; dose could be maintained or increased to a maximum of 84 mg for up to 52 weeks; twice-weekly for 4 weeks, followed by QW for 4 weeks and QW or QOW, depending on efficacy, from weeks 8 to 52802^e^NAOchs-Ross et al., 2019 (TRANSFORM-3) \[[@CR9]\]Phase III, R, DB, AC in elderly (≥ 65 years) patients with TRDFlexible dosing for 4 weeks: 28 mg to start; the dose could be maintained or increased in increments of 28 mg up to a maximum dose of 84 mg7265Total number of patients evaluable for safety1708486*AC* active-controlled (i.e., oral antidepressant), *DB* double-blind, *OL* open-label, *PC* placebo-controlled, *QOW* every other week, *QW* weekly, *R* randomized; *TRD* treatment-resistant depression^a^These patients took esketamine either in period 1 or period 2 of the DB phase, or in the OL phase^b^53 of these patients took esketamine either in period 2 of the DB phase or in the OL phase of this multiphase study^c^182 patients rolled over from TRANSFORM-1 or TRANSFORM-2^d^All patients took esketamine in the previous phase(s) of the study (out of which, 48 patients who were on esketamine in TRANSFORM-1 or TRANSFORM-2 rolled over into SUSTAIN-1)^e^111 patients rolled over from TRANSFORM-3 (of which 55 were on esketamine and 56 were on placebo). One placebo-treated patient from TRANSFORM-3 who transferred to SUSTAIN-2 was treated with an oral antidepressant but did not receive esketamine

Study Population {#Sec4}
----------------

All studies enrolled patients with moderate-to-severe depression, without psychotic features, who met the study definition of TRD (i.e., non-response to two separate and adequate trials of an antidepressant in the current episode of depression, of which one was observed prospectively). Two studies enrolled elderly patients (age ≥ 65 years), and five studies enrolled patients between 18 and 64 years of age. Of note with regard to cardiac effects, patients with cardiovascular disease (cerebrovascular disease with a history of stroke or transient ischemic attack; aneurysmal vascular disease; coronary artery disease with myocardial infarction, unstable angina, or revascularization procedure within 12 months before the start of the trial; hemodynamically significant valvular heart disease such as mitral regurgitation, aortic stenosis, or aortic regurgitation; New York Heart Association Class III--IV heart failure), uncontrolled hypertension (\> 140/\> 90 mmHg), history of hypertensive crisis, or clinically significant electrocardiogram (ECG) abnormalities were excluded from enrollment.

Study Drug {#Sec5}
----------

Eligible patients received esketamine nasal spray (28 mg (only for patients 65 years and older) to 84 mg twice weekly, once weekly, or every other week; Table [1](#Tab1){ref-type="table"}) in combination with an oral antidepressant for 4--52 weeks. In the phase III studies \[[@CR5]--[@CR9]\], patients received a new oral antidepressant \[one of the following options: a selective serotonin reuptake inhibitor (SSRI: escitalopram or sertraline) or a serotonin and norepinephrine reuptake inhibitor (SNRI: duloxetine or venlafaxine extended release)\], which was initiated at the start of the induction phase, whereas in the adjunctive phase II study \[[@CR4]\], no new antidepressant was initiated and patients were permitted to continue their ongoing oral antidepressant treatment. In the placebo-controlled studies, patients randomized to placebo received intranasal study drug \[i.e., water for injection with bittering agent (to imitate the bitter taste of esketamine) and a preservative\] that was provided in a disposable nasal spray device with identical appearance and packaging to that of esketamine nasal spray. Patients self-administered the intranasal study drug at the study site under the direct supervision of a site staff member.

Cardiac Safety Assessments {#Sec6}
--------------------------

Adverse events (including severity, seriousness, and outcomes), vital signs, and ECG were monitored throughout the studies. Severity of adverse events was graded as mild (symptoms were easily tolerated, caused minimal discomfort, and did not interfere with everyday activities); moderate (discomfort caused interference with normal activity); or severe (extreme distress caused significant impairment of functioning or incapacitation, and prevented normal everyday activities).

Vital signs were measured at baseline and all dosing visits (phase II: predose, and at 40 min and 2 h postdose; phase III: predose, and at 40 min, 1 h, and 1.5 h postdose). BP and pulse/heart rate measurements were assessed after the patient had rested for at least 5 min and were measured supine, either with a completely automated device or using manual techniques.

In the phase III studies, as a risk mitigation measure, guidance on BP monitoring on intranasal treatment days was provided to investigators \[i.e., no dosing if predose SBP \> 140 mmHg (\> 150 for age \> 65 years) or DBP \> 90 mmHg; dose interruption if postdose SBP ≥ 200 mmHg (≥ 190 for age \> 65 years) or DBP ≥ 110 mmHg (≥ 100 for age \> 65 years)\]; patients with elevated BPs were referred to a specialist or general practitioner for evaluation and potential treatment \[[@CR18]\].

Single, 12-lead ECGs were performed at pre-specified timepoints after patients had rested in a supine position for at least 5 min. All ECG tracings were sent to a central ECG laboratory and were read by a cardiologist.

The effects of esketamine on cardiac repolarization were assessed in a phase I randomized, positive- and active-controlled (oral moxifloxacin 400 mg) thorough corrected QT (QTc) interval study. Healthy subjects were randomly assigned in a double-blind, crossover manner to single doses of placebo, oral moxifloxacin, or esketamine 84 mg nasal spray in the first three periods, and to esketamine 0.8 mg/kg as a 40-min IV infusion (supratherapeutic dose) in the fourth period. Placebo was given in combination with each of the active treatments.

Statistical Methods {#Sec7}
-------------------

Safety data were analyzed in an All Randomized, Blinded Trials TRD Population \[[@CR4]--[@CR7], [@CR9]\] and in an All Clinical Trials TRD Population \[[@CR4]--[@CR9]\], both including patients who received at least one dose of intranasal study drug.

Increased BP-related adverse events included the following *Medical Dictionary for Regulatory Activities* (MedDRA^®^) (version 20.0) preferred terms: accelerated hypertension; blood pressure abnormal; blood pressure ambulatory abnormal; blood pressure ambulatory increased; blood pressure diastolic abnormal; blood pressure diastolic increased; blood pressure inadequately controlled; blood pressure increased; blood pressure orthostatic abnormal; blood pressure orthostatic increased; blood pressure systolic abnormal; blood pressure systolic increased; diastolic hypertension; hypertension; hypertensive cerebrovascular disease; hypertensive crisis; hypertensive emergency; hypertensive encephalopathy; hypertensive end-organ damage; hypertensive heart disease; labile hypertension; orthostatic hypertension; prehypertension; supine hypertension; and systolic hypertension.

Adverse events related to abnormal heart rate included the following MedDRA^®^ (version 20.0) preferred terms: atrial fibrillation; atrial tachycardia; cardiac fibrillation; extrasystoles; heart rate abnormal; heart rate increased; palpitations; sinus tachycardia; sudden cardiac death; sudden death; supraventricular tachycardia; tachyarrhythmia; tachycardia; tachycardia paroxysmal; and ventricular tachycardia.

Cardiovascular adverse events of clinical interest included, but were not limited to, the following MedDRA^®^ (version 20.0) preferred terms: angina pectoris; cardiac failure acute; chest discomfort; chest pain; and hypertensive heart disease.

### Analyses {#Sec8}

For adverse events, an odds ratio (OR) and a two-sided exact 95% confidence interval (CI) for esketamine/antidepressant versus oral antidepressant/placebo were calculated for the All Randomized, Blinded Trials TRD Population. Results of all other analyses were summarized descriptively.

### Sample Size Determination {#Sec9}

The sample size planned for each study included in the analyses was calculated based on assumptions on efficacy.

Results {#Sec10}
=======

A total of 1708 esketamine nasal spray-treated patients received at least one dose of esketamine in the six completed phase II and III studies, and were included in the All Clinical Trials TRD Population. Of these, 194 (11.4%) were ≥ 65 years. The combined cumulative exposure to esketamine nasal spray in the six phase II/III TRD studies was 611 patient-years (601 patient-years in the phase III studies), and the combined cumulative exposure to placebo nasal spray was 108 patient-years (107 patient-years in the phase III studies). Of the 1601 patients exposed to esketamine nasal spray across the five completed phase III studies, 479 were exposed to esketamine for at least 6 months and 178 were exposed for at least 12 months.

Baseline demographic and disease characteristics for the All Clinical Trials TRD Population are presented in Table [2](#Tab2){ref-type="table"}.Table 2Demographic and baseline characteristics of patients in phase II/III studies of esketamine nasal spray---all clinical trials TRD population^a^CharacteristicEsketamine + oral antidepressant (*N *= 1708)Age (years) Mean (SD)49.1 (12.91) Range18--86Sex \[*n* (%)\] Male634 (37.1) Female1074 (62.9)Race \[*n* (%)\] Asian126 (7.4) Black or African American72 (4.2) White1445 (84.6) Multiple13 (0.8) Other30 (1.8) Not reported/unknown22 (1.3)Baseline body mass index (kg/m^2^) Mean (SD)28.1 (6.00) Range16--67Age when diagnosed with MDD^b^ (years) Mean (SD)33.9 (12.97) Range5--75Duration of current episode^b^ (weeks) Mean (SD)148.7 (238.4) Range4--2288Hypertension status \[*n* (%)\] Yes403 (23.6) No1305 (76.4)*MDD* major depressive disorder, *SD* standard deviation^a^Includes safety evaluable patients from studies cited in Daly et al. \[[@CR4], [@CR7]\], Fedgchin et al. \[[@CR5]\], Popova et al. \[[@CR6]\], Wajs et al. \[[@CR8]\], and Ochs-Ross et al. \[[@CR9]\]^b^*N* = 1705

Increased BP reported as an adverse event occurred in 12.8% of all esketamine-treated patients (Table [3](#Tab3){ref-type="table"}). In the double-blind trials, the rate of increased BP-related adverse events was \~ 3-fold higher in the esketamine/antidepressant group versus the antidepressant/placebo group (11.6% vs. 3.9%; OR 3.2 \[95% CI 1.9--5.8\]); most of the increased BP-related adverse events were considered as mild or moderate (98%) and resolved (94%). BP elevation following initial administrations of study drug did not predict BP elevation following later administrations (data not presented).Table 3Summary of increased blood pressure-related adverse events in esketamine nasal spray phase II/III clinical development studiesAdverse eventsAll randomized, blinded trials TRD population^a^All clinical trials TRD population^b^Esketamine + oral antidepressant (*N* = 571)Oral antidepressant + placebo (*N* = 486)Esketamine + oral antidepressant (*N* = 1708)Increased blood pressure-related adverse events^c^ *n* (%)66 (11.6)19 (3.9)219 (12.8) Odds ratio3.2 95% CI^d^1.9--5.8Increased blood pressure-related events (preferred terms) \[*n* (%)\] Blood pressure diastolic increased6 (1.1)030 (1.8) Blood pressure increased51^e^ (8.9)15 (3.1)168^e^ (9.8) Blood pressure systolic increased4 (0.7)1 (0.2)19 (1.1) Hypertension11 (1.9)3 (0.6)43 (2.5) Hypertensive crisis001^f^ (0.1) Hypertensive heart disease001 (0.1)Seriousness^g^ \[*n* (%)\] Fatal000 Serious1 (1.4)02 (0.8)Outcomes^g^ \[*n* (%)\] Recovered65 (90.3)19 (100.0)238 (90.8) Recovered with sequelae2 (2.8)03 (1.1) Recovering1 (1.4)06 (2.3) Not recovered4 (5.6)015 (5.7)Severity^g^ \[*n* (%)\] Mild51 (70.8)15 (78.9)180 (68.7) Moderate20 (27.8)4 (21.1)78 (29.8) Severe1 (1.4)04 (1.5)*CI* confidence interval, *TRD* treatment-resistant depression^a^Includes safety evaluable patients from studies cited in Daly et al. \[[@CR4], [@CR7]\], Fedgchin et al. \[[@CR5]\], Popova et al. \[[@CR6]\], and Ochs-Ross et al. \[[@CR9]\]^b^Includes safety evaluable patients from studies cited in references Daly et al. \[[@CR4], [@CR7]\], Fedgchin et al. \[[@CR5]\], Popova et al. \[[@CR6]\], Wajs et al. \[[@CR8]\], and Ochs-Ross et al. \[[@CR9]\]^c^Includes all patients who had ≥ 1 occurrences of an adverse event that coded to the MedDRA^®^ preferred terms grouped under 'Increased Blood Pressure-related Events'; the patient is counted only once regardless of the number of events or the number of occurrences^d^The two-sided exact 95% CI in odds ratio of esketamine + oral antidepressant to oral antidepressant + placebo for All Randomized, Blinded Trials TRD Population^e^One event was severe and serious; 2 events in the All Clinical Trials TRD Population were severe and non-serious^f^Event was severe and serious^g^The total number of distinct preferred terms (i.e., preferred terms that refer to separate adverse events reported by individual patients) in the 'Increased Blood Pressure-related Events' group by seriousness/outcome and also by severity

Adverse events related to abnormal heart rate (e.g., palpitations, tachycardia) were reported in 3.0% of all esketamine-treated patients (Table [4](#Tab4){ref-type="table"}). In the double-blind trials, the rate of adverse events related to abnormal heart rate was \~ 2-fold higher in the esketamine/antidepressant versus the antidepressant/placebo group (1.6% vs. 0.8%; OR 1.9 \[95% CI 0.5--8.6\]); most of the events were mild or moderate (96%) and resolved (88%).Table 4Summary of adverse events related to abnormal heart rate in esketamine nasal spray phase II/III clinical development studiesAdverse eventsAll randomized, blinded trials TRD population^a^All clinical trials TRD population^b^Esketamine + oral antidepressant (*N *= 571)Oral antidepressant + placebo (*N *= 486)Esketamine + oral antidepressant (*N *= 1708)Adverse events related to abnormal heart rate^c^ *n* (%)9 (1.6)4 (0.8)52 (3.0) Odds ratio1.9 95% CI^d^0.5--8.6Adverse events related to abnormal heart rate (preferred terms) \[*n* (%)\] Atrial fibrillation002 (0.1) Extrasystoles2 (0.4)03 (0.2) Heart rate increased1 (0.2)03 (0.2) Palpitations3^e^ (0.5)2 (0.4)26^e^ (1.5) Sinus tachycardia01 (0.2)3^f^ (0.2) Tachycardia4 (0.7)1 (0.2)20 (1.2)Seriousness^g^ \[*n* (%)\] Fatal000 Serious001 (1.8)Outcomes^g^ \[*n* (%)\] Recovered8 (80.0)3 (75.0)48 (84.2) Recovered with sequelae001 (1.8) Recovering001 (1.8) Not recovered2 (20.0)1 (25.0)7 (12.3)Severity^g^ \[*n* (%)\] Mild5 (50.0)3 (75.0)43 (75.4) Moderate4 (40.0)1 (25.0)12 (21.1) Severe1 (10.0)02 (3.5)*CI* confidence interval, *TRD* treatment-resistant depression^a^Includes safety evaluable patients from studies cited in references Daly et al. \[[@CR4], [@CR7]\], Fedgchin et al. \[[@CR5]\], Popova et al. \[[@CR6]\], and Ochs-Ross et al. \[[@CR9]\]^b^Includes safety evaluable patients from studies cited in Daly et al. \[[@CR4], [@CR7]\], Fedgchin et al. \[[@CR5]\], Popova et al. \[[@CR6]\], Wajs et al. \[[@CR8]\], and Ochs-Ross et al. \[[@CR9]\]^c^Includes all patients who had ≥ 1 occurrences of an adverse event that coded to the MedDRA^®^ preferred terms grouped under 'Adverse events related to abnormal heart rate'; the patient is counted only once regardless of the number of events or the number of occurrences^d^The two-sided exact 95% CI in odds ratio of esketamine + oral antidepressant to oral antidepressant + placebo for All Randomized, Blinded Trials TRD Population^e^One event was severe and non-serious^f^One event was severe and serious^g^The total number of distinct preferred terms (i.e., preferred terms that refer to separate adverse events reported by individual patients) in the 'Adverse events related to abnormal heart rate' group by seriousness/outcome and also by severity

Cardiovascular adverse events of clinical interest were uncommon (1.3% of all esketamine-treated patients), and were reported at a rate that was similar between the esketamine/antidepressant and antidepressant/placebo groups in double-blind studies (Table [5](#Tab5){ref-type="table"}).Table 5Summary of cardiovascular adverse events of clinical interest in esketamine nasal spray phase II/III clinical development studiesAdverse eventsAll randomized, blinded trials TRD population^a^All clinical trials TRD population^b^Esketamine + oral antidepressant (*N *= 571)Oral antidepressant + placebo (*N *= 486)Esketamine + oral antidepressant (*N *= 1708)Cardiovascular adverse events of clinical interest^c^ *n* (%)3 (0.5)2 (0.4)23 (1.3) Odds ratio1.3 95% CI^d^0.1--15.4Cardiovascular events of clinical interest (preferred terms) \[*n* (%)\] Angina pectoris001 (0.1) Cardiac failure acute001^e^ (0.1) Chest discomfort2^f^ (0.4)015^f^ (0.9) Chest pain1 (0.2)2 (0.4)5^g^ (0.3) Hypertensive heart disease001 (0.1)Seriousness^h^ \[*n* (%)\] Fatal001 (4.3) Serious002 (8.7)Outcomes^h^ \[*n* (%)\] Recovered3 (100)2 (100)21 (91.3) Recovered with sequelae000 Recovering001 (4.3%) Not recovered000Severity^h^ \[*n* (%)\] Mild02 (100)12 (52.2) Moderate2 (66.7)05 (21.7) Severe1 (33.3)06 (26.1)*CI* confidence interval, *TRD* treatment-resistant depression^a^Includes safety evaluable patients from studies cited in references Daly et al. \[[@CR4], [@CR7]\], Fedgchin et al. \[[@CR5]\], Popova et al. \[[@CR6]\], and Ochs-Ross et al. \[[@CR9]\]^b^Includes safety evaluable patients from studies cited in Daly et al. \[[@CR4], [@CR7]\], Fedgchin et al. \[[@CR5]\], Popova et al. \[[@CR6]\], Wajs et al. \[[@CR8]\], and Ochs-Ross et al. \[[@CR9]\]^c^Includes all patients who had ≥ 1 occurrences of an adverse event that coded to the MedDRA^®^ preferred terms grouped under 'Cardiovascular Adverse Events of Clinical Interest'; the patient is counted only once regardless of the number of events or the number of occurrences^d^The two-sided exact 95% CI in odds ratio of esketamine + oral antidepressant to oral antidepressant + placebo for All Randomized, Blinded Trials TRD Population^e^Event was severe and serious, resulting in death^f^One event in the esketamine + oral antidepressant group and three events in the All Clinical Trials TRD Population were severe and non-serious^g^One event was severe and serious, and one event was severe and non-serious^h^The total number of distinct preferred terms (i.e., preferred terms that refer to separate adverse events reported by individual patients) in the 'Cardiovascular Adverse Events of Clinical Interest' group by seriousness/outcome and also by severity

In general, increased BP-related adverse events, abnormal heart rate-related adverse events, and cardiovascular adverse events of clinical interest experienced by esketamine-treated patients had an onset shortly after dosing and resolved by 1.5 h postdose while patients were in the clinic.

In the all-clinical trials TRD population, three serious and severe cardiovascular adverse events related to BP increase were reported for two patients. One event was reported for a 74-year-old male patient whose BP increased from 130/90 to 170/110 mmHg on day 1, 5 min after administration of a 28 mg dose of esketamine, and resolved on the same day. Hypertensive crisis and sinus tachycardia, which began 3 days after the last dose of esketamine and resolved 2 days later, were reported for the second patient, who had a history of hypertension and panic attacks. Cardiac enzymes, chest radiograph, computed tomography angiogram, and echocardiogram for the patient were all normal at the time of the event. The differential diagnosis included a hypertensive episode due to non-compliance with concomitant lisinopril and severe panic attack.

In addition to the above-described cases, a serious and severe unrelated event of lacunar stroke was reported for a 64-year-old female patient with a history of hypercholesterolemia on day 1, 6 h after esketamine nasal spray administration. Magnetic resonance imaging confirmed the ischemic character of the lesion. Given the absence of findings suggestive of an intracranial hemorrhage, the plausible mechanism for this ischemic stroke was considered to be microatheroma. A non-serious adverse event of increased BP was also reported for this patient on day 1. Her BP increased from 116/57 mmHg prior to esketamine dosing to 162/74 mmHg at 40 min postdose, then decreased to 122/58 mmHg at 1 h postdose.

One fatal unrelated event of acute cardiac failure (accompanied by respiratory failure) was reported 5 days after the last dose of esketamine for a 60-year-old male patient with a history of hypertension and obesity. Pulse oximetry, respiratory rate, and BP values for this patient remained normal during his participation in the study; transient nausea and headache, during the first week of the study, were the only adverse events reported for this patient.

In addition, three events were reported as severe and not serious (palpitations for one patient and BP increase for two patients).

In general, BP increases reached a maximum within 40 min of esketamine dosing (consistent with peak plasma concentrations \[[@CR18]\]) and typically returned to the predose range by 1.5 h postdose. Mean BP over time and mean maximum and maximum change from baseline in postdose BP in the 4-week double-blind induction phase of TRANSFORM-1 and TRANSFORM-2 are presented in Figs. [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}, respectively.Fig. 1Mean \[± standard error (SE)\] blood pressure over time from the induction phase of 4-week double-blind studies of patients with treatment-resistant depression (TRD) aged 18--64 years \[[@CR5], [@CR6]\]Fig. 2Mean maximum \[± standard error (SE)\] and maximum change in postdose blood pressure: pooled results from the induction phase of 4-week double-blind studies of patients with treatment-resistant depression (TRD) aged 18--64 years \[[@CR5], [@CR6]\]

Approximately 8--17% of esketamine-treated patients and 1--3% of placebo-treated patients experienced an increase of more than 40 mmHg in SBP and/or 25 mmHg in DBP in the first 1.5 h after administration at least once during the first 4 weeks of treatment. A substantial increase in BP could occur after any dose administered even if smaller BP effects were observed with previous administrations.

The largest mean maximum SBP/DBP increases from predose at any postdose timepoint across all intranasal dosing days were 13.3/8.7 mmHg for esketamine/antidepressant and 6.1/4.9 mmHg for antidepressant/placebo in the two 4-week studies of patients aged 18--64 years (Fig. [2](#Fig2){ref-type="fig"}) and 16.0/9.5 and 11.1/6.8 mmHg, respectively, in the elderly study (TRANSFORM-3).

The percentage of patients (age 18--64 years) with markedly abnormal BP elevation (SBP ≥ 180 mmHg and/or DBP ≥ 110 mmHg) ranged 2.0--4.9% in esketamine/antidepressant group versus 0--0.9% in antidepressant/placebo group across studies/phases and was higher in patients with (5.5--7.6%) versus without (4.1--4.3%) a history of hypertension. The percentages of patients with markedly abnormal BP elevation were higher (11.1% in esketamine/antidepressant vs. 6.2% in antidepressant/placebo) in the elderly, and in the study of elderly patients with (14.6%) versus without (6.5%) a history of hypertension.

No discontinuations occurred due to adverse events related to increased BP in either the esketamine/antidepressant group or the antidepressant/placebo group in the double-blind phases across the two short-term phase III studies in patients 18--64 years of age (pooled TRANSFORM-1 and -2 studies). Thirteen patients who were on esketamine in TRANSFORM-3 (*n* = 2), SUSTAIN-1 (*n* = 2), and SUSTAIN-2 (*n* = 9) discontinued study medication due to adverse events related to increased BP. Overall, discontinuation of esketamine treatment due to adverse events of increased BP and tachycardia occurred in \< 2% of patients across studies/study phases.

In the phase II dose-ranging study, there was no evidence of a clear dose response across the three doses of esketamine in terms of BP changes. In the phase III fixed-dose study TRANSFORM-1, differences between the maximum mean changes in BP between the 56 and 84 mg doses of esketamine were small and not suggestive of a dose response (14.3 and 15.0 mmHg, respectively, for SBP; 8.9 and 9.4 mmHg, respectively, for DBP).

The proportion of patients who initiated a new antihypertensive medication after an acute episode of hypertension was comparable between treatment groups in the short-term double-blind studies \[one (of 17) esketamine/antidepressant patient vs. zero (of two) antidepressant/placebo patients\]. Among the patients without a history of hypertension who participated in the short-term double-blind studies, new antihypertensive medication was initiated by 2.1% (6/280) of patients in the esketamine group \[amlodipine: two (0.7%), captopril: one (0.4%), losartan: one (0.4%), metoprolol: one (0.4%), propranolol: one (0.4%) versus 1.2% (2/171) of patients in the antidepressant/placebo group hydrochlorothiazide: one (0.6%), prazosin: one (0.6%)\].

The proportion of postdose adverse events of increased BP that were treated with a rescue ('as needed') medication on the dosing day in the short-term double-blind studies was 2.2% (two of 93 events) in the esketamine/antidepressant group versus 0% (zero of two events) in the antidepressant/placebo group, and in the long-term open-label safety study, 2.4% (eight of 330 events).

An analysis of adverse events by class of antidepressant did not show any trend or clinically meaningful difference in cardiovascular or BP-related adverse events between patients taking SSRIs and those taking SNRIs. Of note, on dosing days the oral antidepressant was taken at least 3 h after the esketamine nasal spray session to alleviate the potential effect of oral antidepressants on postdose BP, especially for those oral antidepressants (e.g., venlafaxine) that are associated with increased BP.

Across the six phase II/III clinical studies, one esketamine-treated patient, a 69-year-old obese female with a medical history of hypertension, asthma, and diabetes mellitus, had a maximum postdose QTcF (QT corrected by Fridericia's equation) value exceeding 500 ms \[predose QTcF of 406 ms and a postdose QTcF (1 h) of 527 ms\]. The increase in QTcF was reported as an adverse event leading to discontinuation. No adverse sequelae were reported. Ten other esketamine-treated patients had a maximum postdose QTcF value \> 480--500 ms; eight esketamine-treated patients had an increase of QTcF from a baseline value of ≥ 60 ms. Clinically significant findings related to abnormal ECG parameters were reported as adverse events at low incidences for esketamine-treated patients and were generally similar among patients who received esketamine/antidepressant and those who received antidepressant/placebo in controlled studies. One patient, a 40-year-old male, in the long-term safety study (SUSTAIN-2) discontinued treatment due to an adverse event of ventricular arrhythmia, which manifested as premature ventricular complexes in the ECG.

In the phase I thorough QTc study, the mean difference (90% CI) from placebo for change in baseline-corrected QTcF over the 30-h postdose interval ranged from − 2.02 ms (− 4.173 to 0.137) to 2.16 ms (0.018 to 4.310) for the 84 mg intranasal esketamine dose and from − 3.51 ms (− 5.721 to − 1.294) to 4.89 ms (2.676 to 7.102) for the 0.8 mg/kg IV infusion (data on file). These results suggest that therapeutic and supratherapeutic doses of esketamine do not prolong the QTcF interval, which was below the 10 ms threshold specified in the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) E14 guideline \[[@CR19], [@CR20]\] at all timepoints.

The evidence discussed here did not support esketamine having a proarrhythmic potential.

Discussion {#Sec11}
==========

The recent US FDA and EMA approvals of esketamine nasal spray as an antidepressant, in conjunction with an oral antidepressant, for patients with TRD has led to great interest in the field of psychiatry. Publications of phase II and III study data have focused on its efficacy and general safety \[[@CR4]--[@CR9]\]. With this report, the data suggest a low risk of serious cardiovascular outcomes when esketamine is administered intranasally in the clinic setting to patients with TRD and a history of no or controlled hypertension. BP elevations following dosing of esketamine nasal spray were generally transient, asymptomatic, self-limiting, without need for rescue medications, and not associated with serious cardiovascular safety sequalae. No clinically relevant effect on ECG parameters was observed in the esketamine development program.

In both double-blind treatment groups, elderly patients (≥ 65 years) had larger increases in SBPs and DBPs than younger patients, more so among those treated with esketamine/antidepressant than with antidepressant/placebo. This finding is likely a consequence of increased arterial stiffness with advancing age \[[@CR21]\]. This difference in cardiovascular response to esketamine did not appear to increase the risk of adverse cardiac events for elderly patients with TRD.

Almost half (47%) of the 1708 patients exposed to esketamine in the study cohort were enrolled and assessed in a long-term safety study, with 479 patients (28% of the All Clinical Trials TRD Population) exposed to esketamine for at least 6 months. Another strength of our analysis is that the approach to assessment of cardiovascular safety was consistent across the phase II and III studies of esketamine, adding credence to combining patient-level data and confidence in the pooled summary statistics. That said, the generalizability of our study findings may be limited by the exclusion of participants with a history of cardiovascular disease within 12 months before the start of the trials, uncontrolled hypertension at study enrollment, or clinically significant ECG abnormalities. It should also be noted that although acute effects were monitored, potential BP elevations or ECG changes occurring between dosing sessions were not routinely documented. Further monitoring for long-term cardiovascular outcomes of this treatment is warranted. The long-term effects of repeated transient BP increases lasting 1--4 h are unknown.

The results described here provide reassurance on the cardiovascular safety of esketamine nasal spray, when administered to patients without hypertension or with well-controlled hypertension and under the observation of a healthcare provider, as directed by the Spravato™ prescribing information \[[@CR18]\]. Patient screening and careful monitoring of BP and cardiovascular functioning are important during the time patients are receiving treatment with esketamine nasal spray. Patients with cardiovascular and cerebrovascular conditions should not be treated with esketamine if the risk outweighs the benefit in this population (details provided in the Spravato™ prescribing information \[[@CR18]\]).

Conclusions {#Sec12}
===========

Our findings formed the basis for instructions in the Spravato™ prescribing information \[[@CR18]\] regarding predose BP thresholds, BP assessments (i.e., prior to and after dosing at approximately 40 min and subsequently, as clinically warranted), and recommended actions to manage BP elevation.
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